Cartesian Therapeutics, Inc. (RNAC) shares surged 23.56 percent, gaining $1.39 to $7.25 on Tuesday after the late clinical-stage biotechnology company announced a strategic licensing agreement with WestGene Biopharma to advance the development of novel in vivo CAR-T therapies for autoimmune diseases.
The stock is currently trading at $7.25, compared with its previous close of $5.86 on the Nasdaq. During the session, it opened at $7.01 and traded between $7.00 and $9.33. Trading volume reached 2.57 million shares, significantly above its average volume of 172,425 shares.
The partnership is designed to combine Cartesian's expertise in autoimmune cell therapies with WestGene's targeted lipid nanoparticle delivery platform, potentially accelerating the development of next-generation treatments. The companies plan to evaluate proof-of-concept in patients with myasthenia gravis, with the potential to expand into multiple autoimmune disease indications if clinical results are positive.
Cartesian Therapeutics shares have traded between $5.60 and $15.57 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.